Imunon highlights 14.7-month overall survival gain in Phase 2 IMNN-001 ovarian cancer study as Phase 3 trial advances

• Imunon highlighted final Phase 2 results already presented, pointing to a survival benefit for IMNN-001 in newly diagnosed advanced ovarian cancer.
• The update framed the Phase 2 findings as supportive evidence for its ongoing Phase 3 OVATION 3 trial, where survival is the primary endpoint.
• Management described the treatment as avoiding the systemic safety issues that derailed earlier IL-12 programs, supporting continued late-stage development.
• Enrollment in OVATION 3 is running ahead of plan, keeping the company’s targeted enrollment completion in the first quarter of 2029 intact.
• Imunon also cited early MRD study observations already shared, suggesting improved disease clearance signals, while noting the dataset remains too small for efficacy conclusions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609240805PRIMZONEFULLFEED9833152) on September 24, 2026, and is solely responsible for the information contained therein.